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Background: Angiogenesis was suggested to have a significant role in the pathogenesis of 
leprosy. However, the benefit of inhibiting angiogenesis in lepromatous leprosy patients has not 
previously been studied. The purpose of this study was to evaluate angiogenesis in leprosy patients 
before and after treatment with multidrug therapy (MDT) with and without minocycline.
Methods: A total of 40 patients with lepromatous leprosy were enrolled in this study. They were 
categorized into two equal groups (A and B), each formed of 20 patients. Group A received World 
Health Organization MDT, and Group B received MDT combined with minocycline, which has a 
known antiangiogenic effect. Microvascular density (MVD) in dermal granuloma was evaluated 
in both groups by immunostaining with CD31 and CD34 markers before and after 6 months of 
treatment.
Results: With CD31 immunostaining, the mean MVD in Group A significantly decreased 
from 39.1 ± 3.1 vessels (v)/high power field (HPF) to 16.5 ± 2.7 v/HPF, and in Group B it 
significantly decreased from 38.3 ± 2.5 v/HPF to 7.6 ± 1.9 v/HPF. CD34 immunostaining also 
showed a significant decrease of MVD from 42.2 ± 3.1 v/HPF to 18.8 ± 2.4 v/HPF in Group 
A, and in Group B it significantly decreased from 43.7 ± 2.3 v/HPF to 11.5 ± 1.6 v/HPF. The 
reduction of MVD was significantly higher in Group B compared with in Group A (P , 0.0001). 
Moreover, there was a significant reduction in bacterial density (assessed by bacterial index) in 
the cutaneous lesions of in Group B (decreased from 4.9 ± 0.3 to 1.4 ± 0.2) compared with in 
Group A (decreased from 5.1 ± 0.4 to 2.3 ± 0.4).
Conclusion: The synergistic effect of MDT and minocycline seems to be promising in the 
treatment of lepromatous leprosy. It significantly reduces angiogenesis and rapidly eliminates 
lepra bacilli from the skin that enables a rapid control and elimination of the disease.
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Introduction
Leprosy is a well-known chronic infectious disease that is caused by Mycobacterium 
leprae (M. leprae). It has a spectrum of cutaneous responses ranging from tubercu-
loid to lepromatous poles. The incidence of leprosy has declined worldwide after the 
introduction of multidrug therapy (MDT) by the World Health Organization (WHO) 
in 1982;1 however, it is still a public health problem in many countries, which have 
a high rate of endemic infection.2 This was an indicator to modify or change WHO 
MDT, aiming at a more effective, safe, compliant, and shorter-duration regimen that 
is free from the fear of the emergence of resistant lepra bacilli.3
Advances in, and deep understanding of, immunology, pathogenesis, and genet-
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infectious disease and may lead to the development of better 
protocols for treatment and prevention of the disease.4 The 
status of dermal vasculature was considered an important 
underlying pathogenic factor in leprosy, and the study of 
dermal vascular changes in leprosy was a matter of interest 
in previous reports.5 It was observed that there is narrowing, 
tortuosity, dilatation, or occlusion of the skin’s blood vessels 
of lepromatous leprosy patients, especially those located in 
the extremities.6
It was proposed that there are two microvascular architec-
tural patterns observed in cutaneous lesions of leprosy: a dense 
and tortuous mesh of microvessels among the granulomatous 
infiltrate in lepromatous leprosy and a microvessel network 
restricted to the periphery of the granulomas in tuberculoid 
leprosy.7 Moreover, the proliferation and migration of endothe-
lial cells result in the formation of new blood vessels from 
pre-existing vessels, a process that is known as angiogenesis, 
which has also been studied in leprosy. It was proposed that 
there is a significant correlation between angiogenesis and 
bacterial load in cutaneous lesions of lepromatous patients.8
In this study we assessed angiogenesis in lepromatous 
leprosy patients before and after treatment with MDT alone 
and in combination with minocycline, a drug known to have 
an antiangiogenic effect. Moreover, we correlated the changes 
in angiogenesis with the changes in bacterial density (BD) 
in the same cutaneous lesions.
Materials and methods
A multicenter study was carried out on 40 lepromatous   leprosy 
patients recruited from the outpatient clinics of the Derma-
tology Departments in Al-Hussein, Tanta, and   Al-Zahraa 
university hospitals, Egypt. The study was approved by the 
local ethical committee.
Patient selection and grouping
All the patients included were newly diagnosed, and none 
of them had received any treatment for leprosy prior to the 
commencement of the study. The diagnosis of leprosy was 
based on the clinical presentation of bilateral, symmetrical, 
nonscaly erythematous nodular skin lesions, which was con-
firmed by the detection of M. leprae in direct nasal or slit skin 
smear. Exclusion criteria included pregnancy, lactation, known 
hypersensitivity to any of the therapeutic drugs, and serious 
illness or bad general condition. Written consent was signed 
by each patient after full explanation of the nature of the study, 
expected benefits of treatment, and possible side effects.
Patients were categorized into two equal groups (A and B). 
Group A (n = 20) received WHO MDT in the form of monthly 
observed doses of rifampicin (600 mg) and clofazimine 
(300 mg) and an unobserved daily dose of dapsone (100 mg) 
and clofazimine (50 mg). Group B (n = 20) received WHO 
MDT therapy in addition to a monthly observed dose of mino-
cycline (100 mg). Treatment was continued for 6 months.
skin biopsy and processing
A 4 mm punch biopsy was taken from each patient before 
treatment and 6 months after. The first biopsy was usually 
taken from the largest nodular lesion, and the second biopsy 
was taken from nearly the same site. From each specimen, 
four sections (4 µm thick) were prepared – one for routine 
hematoxylin and eosin staining for diagnosis and evaluation 
of the granulomatous reaction, one for modified Ziehl-
Neelsen stain (Wade-Fite method) to record the BD (assessed 
by bacterial index [BI]), and two for immunohistochemical 
staining with anti-CD31 and anti-CD34 monoclonal 
antibodies to assess microvascular density (MVD).
Immunohistochemical staining
Immunohistochemical staining was performed using an 
avidin-biotin peroxidase complex method on formalin-
fixed, paraffin-embedded tissue sections,9 using a 1/50 
dilution of monoclonal CD31 and CD34 antibodies (Dako, 
Glostrup, Denmark). Briefly, tissue sections were mounted on 
3-aminopropyl-triethoxysilane-coated slides and dried over-
night at room temperature. Subsequently, they were dewaxed 
in xylene and rehydrated in graded ethanol. After being 
rinsed with phosphate buffered saline, they were immersed 
in 0.01 mol/L citric acid titrated to pH 6.0 and heated twice 
for 10 minutes in a microwave oven. The primary antibodies 
were then incubated on the sections for 30 minutes. Diamin-
obenzidine was used as a chromagen, and the slides were 
counterstained with Mayer’s hematoxylin.
Microvessel density was assessed by immunostaining for 
CD31 and CD34 according to Weidner.10 Areas with higher 
vascularity (so-called hot-spots) were located at low magni-
fication (×40) and then were counted at ×400 magnification. 
Each positive endothelial cell or group of cells in contact 
with a spot was counted as an individual vessel. The mean 
vessel count from three fields was used as CD34 microvessel 
density or CD31 microvessel density. The assessment of both 
BD and MVD was performed only in the dermal granuloma 
without assessment of the stromal changes.
Microscopic evaluation
BD in each Wade-Fite stained specimen was assessed 
by BI following Ridley’s logarithmic scale (from 1 to 6). Clinical, Cosmetic and Investigational Dermatology 2012:5 submit your manuscript | www.dovepress.com
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The number of solid staining (viable) lepra bacilli was visu-
ally calculated in ten different high power fields (HPF), and 
the mean ± standard deviation (SD) was recorded.
statistical analysis
For quantitative data, the mean and SD were calculated. The 
difference between means was statistically analyzed using 
the Student’s t-test. P , 0.05 was considered statistically 
significant.
Follow-up of the patients
Follow-up of the patients was done monthly for observa-
tion of the monthly doses of treatment and recording of any 
side effects, complications, or lepra reaction. We reported 
two patients in Group A who developed erythema nodosum 
leprosum during the first month of treatment (2 and 3 weeks, 
respectively). The treatment was continued in both patients 
with the addition of oral corticosteroids (40 mg daily for 
15 days then gradually withdrawn). Both patients showed 
significant relief of symptoms within 3 weeks. In Group B, 
no significant side effects or complications were encountered 
during the treatment period.
Results
Clinical data and direct smear
Group A included 16 males and four females. Their 
ages ranged from 25 years to 53 years with a mean of 
32 ± 4.5 years. Group B included 13 males and seven 
females. Their ages ranged from 28 years to 49 years with a 
mean of 34 ± 2.5 years. The duration of the disease ranged 
from 3 weeks to 11 months with a mean of 14 ± 3 weeks. In 
29 patients (72.5%) skin lesions were located on the trunk 
and extremities, whereas in eleven patients (27.5%) the 
lesions were distributed mainly on the extremities. Facial 
involvement was reported in 13 patients (32.5%) and nerve 
thickening in 27 patients (67.5%). M. leprae were detected 
in 16 patients (40%) by nasal smear and in 24 patients (60%) 
by slit skin smears.
Microvascular density
CD31 immunohistochemistry
In Group A, the MVD (number of vessels [v]/HPF) ranged 
from 35 v/HPF to 43 v/HPF with a mean of 39.1 ± 3.1 before 
treatment, whereas after treatment the MVD decreased 
to 16.5 ± 2.7 (ranged from 13 v/HPF to 19 v/HPF). This 
reduction was statistically highly significant (P , 0.001) 
(Table 1). In Group B, the MVD ranged from 35 v/HPF 
to 46 v/HPF with a mean of 38.3 ± 2.5 before treatment, 
which decreased to 7.6 ± 1.9 after treatment (ranged from 
5 v/HPF to 10 v/HPF). This reduction was statistically highly 
significant (P , 0.001) (Table 2).
CD34 immunohistochemistry
In Group A, the mean MVD significantly decreased from 
42.2 ± 3.1 before treatment (Figure 1A) to 18.8 ± 2.4 after treat-
ment (Figure 1B) (Table 1). In Group B, the mean MVD signif-
icantly decreased from 43.7 ± 2.3 before treatment (Figure 2A) 
to 11.5 ± 1.6 after treatment (Figure 2B) (Table 2). There 
was a statistically significant higher reduction (P , 0.001) in 
angiogenesis evaluated by both CD31 and CD34 markers in 
Group B compared with in Group A (Table 3).
Bacterial density
In Group A, BI ranged from 4 (10–100 bacilli/HPF) to 
6 (.1000 bacilli/HPF) with a mean of 5.1 ± 0.4 before treat-
ment, which was significantly decreased to 2.3 ± 0.4 after 
treatment (Table 1). In Group B, the mean BI significantly 
decreased from 4.9 ± 0.3 before treatment (Figure 3A) to 
Table 1 CD31 and CD34 immunostaining and BI before and 
after treatment in group A
Marker Before treatment After treatment P-value
CD31 (v/HPF)
range 
M ± sD
35–43 
39.1 ± 3.1
13–19 
16.5 ± 2.7
,0.001a
CD34 (v/HPF)
range 
M ± sD
37–46 
42.2 ± 3.1
15–23 
18.8 ± 2.4
,0.001a
BI 
range 
M ± sD
 
4–6 
5.1 ± 0.4
 
1–2 
2.3 ± 0.4
 
,0.001a
Note: aP is significant at ,0.05.
Abbreviations: BI, bacterial index; M, mean; sD, standard deviation, v/hPF, vessel/
high power field.
Table 2 CD31 and CD34 immunostaining and BI before and 
after treatment in group B
Before treatment After treatment P-value
CD31 (v/HPF)
range 
M ± sD 
35–46 
38.3 ± 2.5
5–10 
7.6 ± 1.9
,0.001a
CD34 (v/HPF)
range 
M ± sD
40–48 
43.7 ± 2.3
8–13 
11.5 ± 1.6
,0.001a
BI 
range 
M ± sD
 
4–6 
4.9 ± 0.3
 
0–1 
1.4 ± 0.2
 
,0.001a
Note: aP is significant at ,0.05.
Abbreviations: BI, bacterial index; M, mean; sD, standard deviation, v/hPF, vessel/
high power field.Clinical, Cosmetic and Investigational Dermatology 2012:5 submit your manuscript | www.dovepress.com
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1.4 ± 0.2 after treatment (Figure 3B) (Table 2). There was a 
statistically significant higher reduction (P , 0.001) in BD 
in Group B compared with in Group A (Table 3).
Discussion
Angiogenesis is considered to be a fundamental event 
in many conditions. The major role of angiogenesis was 
reported in relation to neoplastic conditions and malig-
nancies that need an ongoing blood supply to grow and 
expand.11 Abnormal angiogenesis was also implicated in 
other conditions such as rheumatoid arthritis, inflamma-
tion, and degenerative eye conditions, in addition to many 
biological processes such as development, reproduction, and 
wound repair.12 In dermatological disorders, angiogenesis 
was implicated mainly in psoriasis,13 and to a lesser extent 
in skin aging and photoaging.14
Drugs that inhibit angiogenesis were used primarily in 
the treatment of malignancy. The role of these antiangiogenic 
or antivascular therapies in the treatment of cancer became 
important after the establishment of the relationship between 
angiogenesis and tumor growth.15 Inhibition of angiogenesis 
growth factors and transfer of antiangiogenesis genes were 
proposed as basic mechanisms of antiangiogenic drugs.16 The 
target receptors of antiangiogenic drugs include   PtdIns-4,5-P2 
that regulate vessel stability,17 vascular endothelial growth 
factor receptor key proteins,18 and Cap43 calcium-inducible 
genes.19
There are certain drugs which have  an antiangiogenic effect 
and are used in the treatment of some skin diseases, such as 
chloroquine, which was suggested to have a beneficial effect in 
the treatment of discoid lupus erythematosus due to its antian-
giogenic properties.20 Thalidomide also has an antiangiogenic 
effect and is currently used in the treatment of different derma-
tological conditions including lepra reaction,21 sclerodermatous 
cutaneous reaction of graft versus host disease,22 and Jessner’s 
lymphocytic infiltration of the skin.23
Recently, rifampicin, which is a component of MDT for 
leprosy, was suggested to have promising antiangiogenic 
effects that may enable its use as an effective antitumor agent.24 
Minocycline was also reported as one of the drugs that inhibit 
angiogenesis,25 and it is known to have an important role in 
the treatment of leprosy as a main component of rifampicin, 
ofloxacin, and minocycline (ROM) therapy.26 However, the 
mechanism of action of both drugs in the treatment of leprosy 
remains unclear. Is it due to their antimicrobial effect only 
or due also to their antiangiogenic effect?
AB
Figure 1 CD34 immunostaining (group A) shows high microvessel density before 
treatment (A) that decreased after treatment (B) (×100 and ×400).
AB
Figure 3 Fite stain (group B) shows higher density of viable and intact Mycobacterium 
leprae  before  treatment  (A)  compared  with  a  few  and  fragmented  bacilli  after 
treatment (B) (×1000).
Table 3 CD31 and CD34 immunostaining and BI before and 
after treatment in both groups
Group A 
(n = 20)
Group B 
(n = 20)
P-value
CD31 (v/HPF) 
Before treatment 
After treatment 
39.1 ± 3.1
16.5 ± 2.7
38.3 ± 2.5
7.6 ± 1.9
 
0.37 
,0.001a
CD34 (v/HPF) 
Before treatment 
After treatment 
42.2 ± 3.1
18.8 ± 2.4
43.7 ± 2.3
11.5 ± 1.6
 
0.09 
,0.001a
BI 
Before treatment 
After treatment
5.1 ± 0.4
2.3 ± 0.4
4.9 ± 0.3
1.4 ± 0.2
 
0.08 
,0.001a
Note: aP is significant at ,0.05.
Abbreviations: BI, bacterial index; M, mean; sD, standard deviation, v/hPF, vessel/
high power field.
AB
Figure 2 CD34 immunostaining (group B) shows high microvessel density before 
treatment (A) that significantly decreased after treatment (B) (×100 and ×400).Clinical, Cosmetic and Investigational Dermatology 2012:5 submit your manuscript | www.dovepress.com
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To our knowledge, no previous studies have evaluated 
the efficacy of these antiangiogenic drugs on angiogenesis 
in cutaneous lesions of lepromatous leprosy patients, but a 
few studies monitor angiogenesis in the spectrum of leprosy. 
Bhandarkar et al8 studied angiogenesis in 32 leprosy patients 
using CD31 as a marker for microvessel density. The MVD 
of lepromatous leprosy lesions was (44.0 ± 9.8 v/HPF). 
We found a lower MVD value with a CD31 marker in lep-
romatous leprosy (39.1 ± 3.1 in Group A and 38.3 ± 2.5 in 
Group B), and with a CD34 marker we found a higher value 
(42.2 ± 3.1 in Group A and 43.7 ± 2.3 in Group B), which 
was close to that encountered by Bhandarkar et al. This may 
suggest the benefit of using more than one marker (CD31, 
CD34) in the assessment of angiogenesis.
Kim et al27 also found a significant increase of MVD 
in lepromatous leprosy lesions compared with in normal 
skin, with an overall increase in the mean number of vessels 
from tuberculoid leprosy through borderline (tuberculoid 
and lepromatous) to lepromatous leprosy lesions. The MVD 
values in lepromatous leprosy were higher (104.40 ± 27.71) 
compared with our results. This can be explained by the use 
of a different vascular marker (Factor VIII-related antigen) 
or a different counting system.
These studies suggested that angiogenesis could be evalu-
ated by using different vascular markers. In the current study 
we preferred to use two markers (CD31 and CD34) in the 
assessment of angiogenesis for proper evaluation of MVD 
and to minimize false positive results. Both CD31 and CD34 
are known as effective markers in identifying blood vessels 
and were proposed also to be good prognostic markers of 
neoangiogenesis.28,29
The significant reduction of MVD and BD in Group 
A, which was treated with MDT, may prove the possible 
antiangiogenic effect of rifampicin in addition to its anti-
microbial effect. Rifampicin was suggested to exert its 
antiangiogenic effect through inhibition of the expression 
of angiogenesis-associated genes with downregulation 
of proangiogenic genes and inhibition of microvascular 
endothelial cell proliferation.24 In a manner comparable 
with the action of endostatin, the endogenous angiogenesis 
inhibitor is known to downregulate a variety of growth and 
angiogenesis-related genes in a wide range of endothelial 
lineage cells.30
In Group B, minocycline 100 mg, which is known to 
have antiangiogenic properties, was added to MDT as a 
monthly dose, aiming to potentiate the antiangiogenic effi-
cacy of the classic MDT regimen. Although minocycline 
has different mechanisms of action from its antimicrobial 
properties, such as inhibition of collagenase activity,31 and 
its anti-inflammatory effect through reduction of cytokines 
and pro-inflammatory protein expression,32 it also possesses 
inhibitory properties of angiogenesis.25 This antiangiogenic 
effect of minocycline may contribute to the direct inhibition 
of matrix metalloproteinase activity and also to the inhibi-
tion of vascular endothelial growth factor-induced smooth 
muscle cell migration.33
In the present work the reduction of MVD was signifi-
cantly higher in Group B than in Group A using both   markers. 
These results may suggest the presence of a synergistic effect 
of both minocycline and rifampicin as antiangiogenic drugs in 
addition to their antimicrobial effect. Moreover, the absence 
of any side effects or lepra reaction in Group B compared 
with in Group A may add a new benefit for the combination 
of MDT with minocycline.
Another important finding in this work is the significantly 
higher reduction in BI in Group B compared with in Group A. 
This may suggest that the addition of minocycline to the 
MDT can cause a more rapid elimination of lepra bacilli 
from cutaneous lesions of lepromatous leprosy patients. This 
rapid elimination of lepra bacilli from cutaneous lesions and 
also from mucous membranes is helpful in decreasing the 
transmission of the disease and maintaining the standard 
target of elimination of leprosy.
Conclusion
To our knowledge, this is the first work that assesses 
angiogenesis in leprosy patients after treatment with 
antiangiogenic drugs. The synergistic antiangiogenic effect of 
both minocycline and rifampicin was found to be promising 
and effective in the treatment of leprosy. Moreover, this 
combination showed an advantage of rapid elimination of 
M. leprae from the cutaneous lesions of lepromatous leprosy 
patients and decreased the possibility of the occurrence of 
lepra reaction. We hope that this regimen will be considered in 
wide-scale studies, especially in endemic areas of leprosy.
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